One step closer to rotavirus vaccination for children with HIV

August 16, 2001

Please note that if you are outside North America the embargo for Lancet Press material is 0001 hours Uk Time Friday 17th August 2001.

Results of a hospital-based study in Malawi published in this week's issue of THE LANCET suggest that children with HIV infection could potentially benefit from vaccination against rotaviruses, the main cause of severe, dehydrating diarrhoea in infants and young children throughout the world.

An estimated 500,000-870,000 children die every year from rotavirus diarrhoea in less-developed countries. Diarrhoeal disease is a leading cause of illness and death in HIV-infected children in these areas; however, use of rotavirus vaccines in children with HIV infection is not recommended, pending further research into the outcomes of children infected with both diseases. Nigel Cunliffe and colleagues from Liverpool University, UK, and the Wellcome Trust Research Laboratories, College of Medicine, Blantyre, Malawi, examined the effect of HIV infection on the clinical presentation and outcome of rotavirus gastroenteritis in Malawian children.

Children younger than 5 years who were treated for acute gastroenteritis at the Queen Elizabeth Central Hospital in Blantyre were enrolled. Those with rotavirus diarrhoea, with and without HIV infection, were followed up for up to 4 weeks after hospital discharge. 786 inpatients (average age 8 months, 34% of whom were HIV-1-infected), and 400 outpatients (average age 9 months, 16% of whom were HIV-1-infected), were enrolled. Rotavirus was detected less frequently among HIV-1-infected children than among HIV-1-uninfected children (30% compared with 41%). There was no difference in rotavirus disease severity for hospitalised children with and without HIV infection, but HIV-infected children were more likely to die during follow-up (22% compared with 0%). Shedding of rotavirus at follow-up was more common among HIV-infected children (21% compared with 4%), although this was not associated with increased incidence of diarrhoea.

Nigel Cunliffe comments:"Our study should now encourage careful studies of the safety of rotavirus vaccines in HIV-infected infants. The possible effect of rotavirus vaccine on host HIV disease needs assessment, and the possibility of prolonged excretion of vaccine virus should be considered. Such studies would represent a significant advance towards the goal of reducing childhood mortality from rotavirus across Africa, through the routine rotavirus vaccination of infants."
-end-
Contact: Dr Nigel A Cunliffe, Department of Medical Microbiology and Genito-Urinary Medicine, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, UK; T) 44-151-706-4381; F) 44-151-706-5805; E) N.A.Cunliffe@liverpool.ac.uk

Lancet

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.